UNSPSC 51393410: Acefylline clofibrol

This classification denotes a bronchodilator with the molecular formula C19H21ClN4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WY672D78VW, chemically known as 7h-purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-, 2-(4-chlorophenoxy)-2-methylpropyl ester but more generally known as acefylline clofibrol, which bears US NIH Compound Identifier 68898. European Medicines Agency schedules Acefylline clofibrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05206MIG.

UNSPSC 51393410 Acefylline clofibrol is a Commodity code nominally tracking a specific pharmaceutical compound, but recent state and local opportunities tagged to this code reflect broader pharmaceutical procurement activity—principally naloxone and drug deactivation systems, and exploratory direct-to-manufacturer prescription programs. The actual buying activity under this code spans emergency medical supply procurement by county health agencies and state health departments evaluating new pharmacy benefit models. Issuing bodies include county government health procurement offices and state health and human services agencies, each operating distinct procurement mechanisms for pharmaceutical and medical-supply acquisition.

Recent activity shows Seminole County, Florida issuing an IFB (IFB60459723LAS, due July 26, 2023, posted June 30, 2026) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county community health building, shipping and delivery included, and the Texas Health and Human Services Commission issuing an RFI (HHS0017013, posted April 3, 2026) to assess vendor capacity for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and wholesaler channels. Geographic activity spans Florida and Texas in the recent record. The mismatch between the code's nominal scope—a specific pharmacological agent—and the actual procurement activity suggests this code may be receiving miscoded filings or the code itself may be a catch-all for pharmaceutical-related state and local contracting that does not map precisely to individual drug compounds.